Lucas Ward
Stock Analyst at Ascendiant Capital
(0.58)
# 4,217
Out of 5,182 analysts
30
Total ratings
26.67%
Success rate
-36.39%
Average return
Main Sectors:
Stocks Rated by Lucas Ward
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SXTP 60 Degrees Pharmaceuticals | Maintains: Buy | $11 → $4.2 | $2.22 | +89.19% | 5 | Apr 9, 2026 | |
| ACON Aclarion | Maintains: Buy | $23 → $7 | $3.17 | +120.82% | 6 | Mar 25, 2026 | |
| HSCS HeartSciences | Maintains: Buy | $9.2 → $8 | $1.97 | +306.09% | 5 | Mar 24, 2026 | |
| LIQT LiqTech International | Maintains: Buy | $4.2 → $4.3 | $1.86 | +131.18% | 7 | Mar 10, 2026 | |
| VVOS Vivos Therapeutics | Maintains: Buy | $6.5 → $5.5 | $1.35 | +307.41% | 5 | Dec 3, 2025 | |
| VMAR Vision Marine Technologies | Maintains: Buy | $135,000 → $108,000 | $1.87 | +5,775,301.07% | 2 | Jul 29, 2024 |
60 Degrees Pharmaceuticals
Apr 9, 2026
Maintains: Buy
Price Target: $11 → $4.2
Current: $2.22
Upside: +89.19%
Aclarion
Mar 25, 2026
Maintains: Buy
Price Target: $23 → $7
Current: $3.17
Upside: +120.82%
HeartSciences
Mar 24, 2026
Maintains: Buy
Price Target: $9.2 → $8
Current: $1.97
Upside: +306.09%
LiqTech International
Mar 10, 2026
Maintains: Buy
Price Target: $4.2 → $4.3
Current: $1.86
Upside: +131.18%
Vivos Therapeutics
Dec 3, 2025
Maintains: Buy
Price Target: $6.5 → $5.5
Current: $1.35
Upside: +307.41%
Vision Marine Technologies
Jul 29, 2024
Maintains: Buy
Price Target: $135,000 → $108,000
Current: $1.87
Upside: +5,775,301.07%